ClinicalTrials.gg
RecruitingNCT06380673TEHITIUpdated May 8, 2026

Stepwise Heat-Denaturated Protein Introduction for Tolerance Induction in Food Allergy

An interventional study of Implementation of cow's milk in decreasingly heated forms and Implementation of heated cow's milk in Food Allergy and Cow Milk Allergy, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 5 sites in Belgium. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Primary conditionMilk HypersensitivityRegistry: Food HypersensitivityReclassifiedWhy we changed it
Registry
Food Hypersensitivity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Milk Hypersensitivity
Why
  1. The study's listed conditions name Milk Hypersensitivity, a narrower term within Food Hypersensitivity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
1 Year to 18 Years
Sex
All
01

Study summary

This interventional study aims to validate an early heated protein introduction protocol in cow's milk allergic children who already developed tolerance towards extensively heated cow's milk, in order to speed up the development of complete cow's milk tolerance. Natural complete tolerance induction towards cow's milk takes several years of strict cow's milk avoidance with high risk of anaphylaxis by accidental cow's milk intake. By shortening the time towards complete tolerance, not only the quality of life of both children and parents ameliorates drastically, the time frame for potential anaphylactic reactions is also strongly reduced and can be considered as a preventive strategy to reduce allergic reactions too. Moreover, this strategy has proved efficient for hen's egg allergy. The main question this study wants to answer is whether a 12 months stepwise heated cow's milk introduction (either by gradual reduction of the cooking time or by the use of the Flemish Milk Ladder) in 20'-cooked cow's milk tolerant subjects, results in a larger proportion of complete cow's milk tolerant children after 12 months compared to natural tolerance induction (with 20' cooked milk introduction only).

Read the detailed description

WP 1: Gradual introduction of less heated cow's milk proteins in 20'-cooked cow's milk tolerant children.

When inclusion criteria are met and informed consent from the parents (and when old enough, assent from the children) is obtained, children will be included in the trial. During the inclusion visit an open 20' cooked milk oral food challenge (OFC) needs to be passed in the hospital. Each visit a validated pedQuality of life (QoL) questionnaire will be taken and blood will be drawn to determine baseline specific IgE (sIgE) and IgG4 to cow's milk. Subjects (n=75) are randomized in a 1/1/1 ratio across three arms for 12 months to study the arm's tolerance inducing capacity (see Arms and Interventions for more information). After 6 months patients are invited for an intermediate visit. After 12 months, a OFC with unheated milk will be performed in all children during their challenge visits. Three months after the OFC, the children will be invited for a termination visit. Children who did not pass the OFC with unheated cow's milk after 12 months, will be invited to an observational 48 months follow-up study, in order to later-on retrieve the potential moment of complete cow's milk tolerance induction by clinical files.

WP2: Study of the immunological mechanisms (Treg and Breg induction and switch to IgG4-producing B cells).

Venous blood will be taken from all 75 children recruited for WP1 at enrolment and at the challenge and termination visit and from 15 healthy age-matched children, after obtaining children's oral or written assent (where appropriate) and parent's informed consent. Peripheral blood mononuclear cells (PBMCs) will be isolated and stimulated by cow's milk proteins as well as a positive control. Membrane markers associated with regulatory activity on T cells will be studied by flow cytometry (FC), as well as cytokine production in the supernatant by meso scale discovery. Furthermore, B cells will be studied after PBMC stimulation by FC. Cow's milk specific IgG4 and cytokine production will also be studied in this culture supernatant.

WP3: In vitro BATs to mimic the outcome of OFC.

In vitro Basophil activation tests (BATs) will be fine-tuned by preparing extracts for 20', 15', 10', 5' cooked and fresh cow's milk. Fine-tuning will include the comparison of new protein extract batches with the first batches, the absence of background basophil activation upon contact with the lowest dose of allergen extract and the comparison of basophil activation of healthy and of allergic children in different phases of cow's milk tolerance, who should show differences depending on the grade of tolerance. After fine-tuning, BATs will be performed as described above with 3 (or 5) extracts from cow's milk at baseline, challenge visit and termination visit in all children recruited within the study.

02

Conditions studied

  • Food Allergy
  • Cow Milk Allergy

Browse trials for

03

In context

Milk Hypersensitivity Reclassified

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

This study's planned enrollment of 90 is above the median of 68 across 95 interventional studies indexed under Milk Hypersensitivity.

Browse Milk Hypersensitivity studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 963 studies on the registry; 267 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Milk Hypersensitivity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Food Hypersensitivity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children (1-18y) had or have a clinical diagnosis of IgE mediated cow's milk allergy based on positive history as well as skin prick testing and/or specific IgE detection by CAPtest in an allergy clinic.
  • Children are at least 12 months old before introduction of heated cow's milk is considered.
  • Children did not suffer from grade 4 anaphylaxis due to cow's milk-ingestion at presentation.
  • Children have specific IgE levels to Bos d 8 below 1.2 kU/mL and/or children passed 20' cooked cow's milk provocation test executed on clinical judgement.

Exclusion criteria

Exclusion Criteria:

  • Children had grade 4 anaphylaxis due to cow's milk ingestion.
  • Children are younger than 12 months old at the moment of passing 20' cooked cow's milk OFC.
  • Parents are not able or not willing to adhere to a specific cow's milk protein-containing diet on a regular basis at home.
  • Multiple food allergy, not compatible with any of the choices in the Flemish Milk Ladder.
  • Parents and/or children are not willing to give IC/assent.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Other
    Stepwise introduction using gradually shorter heating of cow's milk proteins

    Step 1: open introduction of 20' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months. Step 2: open introduction of 15' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months. Step 3: open introduction of 10' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months. Step 4: open introduction of 5' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.

    Other: Implementation of cow's milk in decreasingly heated forms

  • Other
    Stepwise introduction using the Flemish Milk Ladder

    The first 5 steps of the Flemish Milk Ladder (each containing a, b and c part) will be gradually introduced at home, each step for 21 days (2-3X a week during 3 consecutive weeks after which 3 days "rest"). We consider the 6th step the equivalent of tolerance induction so step 6 will be allowed once the OFC with uncooked milk is passed.

    Other: Implementation of cow's milk in decreasingly heated forms

  • Other
    Control arm with introduction of 20' cooked cow's milk

    Step 1: open introduction of 20' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 12 months.

    Other: Implementation of heated cow's milk

  • Other
    Healthy age-matched subjects

    For work package 2, 15 healthy age-matched subjects are included to compare immunological mechanisms with.

    Other: No intervention

Interventions

  • OtherImplementation of cow's milk in decreasingly heated forms

    Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

  • OtherImplementation of heated cow's milk

    Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.

  • OtherNo intervention

    Healthy subjects undergo no intervention.

06

What researchers measure

Primary outcomes

  1. Complete cow's milk tolerance after 12 months of stepwise heated cow's milk introduction

    We here want to test the hypothesis that a total period of 12 months stepwise heated cow's milk introduction (either by gradual reduction of the cooking time or by the use of the Flemish Milk Ladder) in 20'-cooked cow's milk tolerant subjects, results in a larger proportion of complete cow's milk tolerant children after 12 months compared to natural tolerance induction (with 20' cooked milk introduction only).

    Time frame: 12 months

Secondary outcomes

  1. Time to complete tolerance in all three arms

    We will study how long it takes for the subjects of each arm to develop complete tolerance toward cow's milk.

    Time frame: 12 months

  2. Quality of life in all three arms

    We will compare Quality of life (QoL) in each arm by comparing the questionnaires filled out by subjects and their parents in each arm.

    Time frame: 12 months

  3. Clinical reactions

    We will compare the presence of clinical reactions after food introduction at home in each arm. Clinical reactions could be anaphylaxis, rhinitis, atopic dermatitis and so forth.

    Time frame: 12 months

  4. Side effects

    We will compare the presence of side effects after food introduction at home in each arm. Side effects could be development of unpleasant taste, refusal of other food, development of eosinophilic esophagitis and so forth.

    Time frame: 12 months

  5. IL-10-producing cow's milk specific regulatory T and B cells

    We will study the induction of IL-10-producing cow's milk specific Treg cells and Breg cells in vitro paralleling tolerance induction. Blood samples are drawn at enrolment, at challenge and termination visit.

    Time frame: Three times in 12 months

  6. BATs to mimic the outcome of cow's milk provocation tests

    We will study whether we can correlate the results of the in-house developed in vitro Basophil activation tests (BAT) with different heated cow's milk-containing extracts to the results of the cow's milk provocation test after 12 months. Blood samples are drawn at enrolment, at challenge and termination visit.

    Time frame: Three times in 12 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06380673
Responsible party
Dominque Bullens (Clinic Head in Pediatrics-Allergy at UZ Leuven, Head of the Allergy and Clinical Immunology Research group at KU Leuven (prof., dr.), Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Apr 24, 2024
Start date
Apr 22, 2024
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
May 8, 2026

Study contacts

Dominique MA Bullens, Prof. MD
Contact
dominique.bullens@kuleuven.be
+32016343801
Marleen Jannis
Contact
marleen.jannis@uzleuven.be
+32016343801
Jasmine Leus, MD
principal investigator · Maria Middelares Hospital, Gent
Katrien Coppens, MD
principal investigator · Imelda Hospital, Bonheiden
Sophie Verelst, MD
principal investigator · KU Leuven and Jessa Hospital, Hasselt
Kate Sauer, MD
principal investigator · AZ Sint-Jan AV

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion